📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-18 17:35
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Alivus Life Sciences to acquire 76% stake in IQGenX Pharma for ₹9.12 crore
Alivus Life Sciences has announced the acquisition of a 76% majority stake in IQGenX Pharma Private Limited for a consideration of ₹9.12 crore (INR 91.2 million). Founded in October 2016, IQGenX is a CRO specializing in formulation development for oral solids, sterile injectables, and ophthalmic solutions across regulated markets. The acquisition enhances Alivus's CDMO service offerings by adding end-to-end capabilities from API synthesis to formulation development, bioequivalence, and regulatory filings. The transaction is subject to customary closing conditions and is expected to close by the end of calendar year 2026.
Confidence: HIGH
What changedAlivus is expanding beyond pure-play API manufacturing by acquiring majority control (76%) of formulation CRO IQGenX.
Why it mattersWhile the deal value is small (₹9.12 crore vs ₹3,333 crore net worth), it provides Alivus with formulation development and regulatory filing capabilities to offer integrated CDMO solutions, particularly in oncology.
Stake acquired: 76%Acquisition consideration: INR 91.2 millionTarget founding year: October 2016Expected completion timeline: End of current calendar year
📅 Short termMinor impact on near-term financials given the modest acquisition size of ₹9.12 crore, but positive sentiment regarding CDMO capability expansion.
📈 Long termStrategically broadens Alivus's value proposition from pure-play APIs to end-to-end CDMO services (formulation R&D to commercial manufacturing), aiding higher-margin regulated market expansion.
⚠ Risk flags
- Integration execution risk of CRO operations
- Pending closure subject to customary condition precedents
Key Highlights
Acquisition of 76% equity stake in IQGenX Pharma for ₹91.2 million (₹9.12 crore)
Target is a CRO established in October 2016 focusing on oral solids, sterile injectables, and ophthalmics
Expands Alivus's CDMO capabilities into pre-formulation, clinical supplies, and regulatory dossier filings
Transaction expected to close by the end of calendar year 2026
👀 What to Watch
Track the completion of customary conditions precedent by end-CY2026 and monitor subsequent CDMO order inflow and margin contribution from integrated formulation-API offerings.
Alivus to Acquire 76% Stake in IQGEN-X Pharma for ~₹9.12 Cr to Expand CDMO Capabilities
Alivus Life Sciences has approved the acquisition of a 76% stake in IQGEN-X Pharma Private Limited for an aggregate cash consideration of approximately ₹9.12 crore. IQGEN-X operates in formulation development for oral solids, sterile injectables, and ophthalmic solutions, reporting FY26 revenue of ₹3.48 crore. The transaction aims to provide end-to-end API and CDMO capabilities and is scheduled to close by December 6, 2026. Given Alivus's quarterly revenue base exceeding ₹670 crore, this is a minor capability-focused bolt-on acquisition with negligible near-term financial impact.
Confidence: HIGH
What changedAlivus Life Sciences signed a share purchase agreement to acquire 76% controlling interest in formulation developer IQGEN-X Pharma for ~₹9.12 crore.
Why it mattersEnables Alivus to offer end-to-end solutions spanning API manufacturing and formulation development in regulated markets, strengthening its CDMO business pipeline.
Acquisition consideration: approx INR 9.12 croresEquity stake acquired: 76%Target FY26 turnover: INR 348 LacsTarget FY25 turnover: INR 318.2 LacsCompletion timeline: December 6, 2026Deal value vs Net worth: ~0.27%
📅 Short termNeutral to mildly positive; minimal financial impact on immediate quarterly numbers given the small revenue base of the target (~₹3.48 crore).
📈 Long termEnhances long-term CDMO offerings by integrating formulation development capabilities for high-value injectable and ophthalmic therapies.
⚠ Risk flags
- Execution and integration risks associated with scaling formulation R&D services.
- Pre-conditions in Share Purchase Agreement must be met prior to December 6, 2026.
Key Highlights
Board approved acquisition of 76% equity stake (8,60,589 shares) in IQGEN-X Pharma for ~₹9.12 crore in cash.
Target entity reported FY26 turnover of ₹348.0 lakh, compared to ₹318.2 lakh in FY25 and ₹267.5 lakh in FY24.
Transaction completion target is December 6, 2026; includes a fallback Business Transfer Agreement structure if conditions are unmet.
Acquisition adds formulation development capabilities in sterile injectables, oral solids, and ophthalmics to Alivus's CDMO suite.
👀 What to Watch
Track the targeted transaction closure by December 6, 2026, and management commentary in upcoming earnings calls regarding CDMO cross-selling opportunities.
₹5 Final Dividend: Alivus Life Sciences Schedules 15th AGM for September 8, 2026
Alivus Life Sciences (formerly Glenmark Life Sciences) has issued a notice for its 15th Annual General Meeting (AGM) to be held on September 8, 2026. The board has recommended a final dividend of ₹5 per equity share (250% of the ₹2 face value) for FY 2025-26, subject to shareholder approval. The cut-off date for determining dividend and e-voting eligibility is September 1, 2026. Other agenda items include the re-appointment of Chairman Mr. Hiren Patel and ratification of cost auditor remuneration of ₹0.50 million.
Confidence: HIGH
What changedThe company has formalized the date for its 15th AGM and confirmed the specific dividend amount and voting timelines for shareholders following its name change from Glenmark Life Sciences.
Why it mattersThis is a key governance event that confirms the final dividend payout for the previous fiscal year and ensures leadership continuity under the Nirma Group ownership.
Final Dividend: ₹5 per shareDividend as % of Face Value: 250%AGM Date: September 8, 2026Cut-off Date: September 1, 2026Cost Auditor Remuneration: ₹0.50 million
📅 Short termThe stock may see mild positive sentiment leading up to the September 1 cut-off date as investors position for the ₹5 dividend.
📈 Long termLimited structural impact from this routine filing; however, the re-appointment of leadership from the Nirma Group signals stability post-acquisition.
Key Highlights
Final dividend of ₹5 per equity share recommended for the financial year ended March 31, 2026.
15th Annual General Meeting scheduled for September 8, 2026, at 3:00 PM IST via video conferencing.
Cut-off date for e-voting and dividend eligibility set for September 1, 2026.
Proposed remuneration of ₹0.50 million plus taxes for Cost Auditors Kirit Mehta & Co. LLP for FY 2026-27.
Re-appointment of Mr. Hiren Patel as a Non-Executive Director, who attended 3 out of 4 board meetings in FY 2025-26.
👀 What to Watch
Investors should ensure their bank details are updated with depositories before the September 1, 2026 cut-off date to receive the dividend. Monitor the company's execution of its strategy to launch 4 new molecules per year in the Japan market as discussed in the annual report.
6.4% Revenue Growth in Q1 FY27; Non-GPL Business Surges 26.5% as Margins Hit 36.6%
Alivus reported Q1 FY27 revenue of ₹640 cr, up 6.4% YoY, despite a sharp 52.6% decline in the Glenmark Pharma (GPL) segment due to inventory rationalization. The non-GPL business grew 26.5% YoY, demonstrating successful revenue diversification. Profitability saw a significant boost with EBITDA margins expanding 650 bps to 36.6% and PAT reaching ₹160 cr. Management has guided for 10-12% revenue growth for FY27, backed by a ₹540 cr capex plan and the Solapur plant becoming operational in Q3 FY27.
Confidence: HIGH
What changedThe company has successfully shifted its growth reliance toward non-GPL clients and high-margin new launches, achieving record EBITDA margins of 36.6%.
Why it mattersThe transition to a more diversified client base and the focus on high-potent APIs ($82bn market) reduces concentration risk and improves the structural margin profile of the business.
Q1 Revenue: ₹640 crEBITDA Margin: 36.6%FY27 Capex Guidance: ₹540 crCapex vs Net Worth: 16.2%Non-GPL Revenue Growth: 26.5%GPL Segment Decline: 52.6%
📅 Short termThe market is likely to react positively to the strong margin expansion and the resilience of the non-GPL portfolio despite the drag from the GPL segment.
📈 Long termStructural growth is supported by a robust pipeline of 29 high-potent APIs and significant capacity expansion, positioning the company for higher-value regulated market opportunities.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Client concentration (GPL still significant despite decline)
- Geopolitical risks impacting raw material pricing
- Lumpy nature of CDMO business
Key Highlights
Non-GPL business grew 26.5% YoY, effectively offsetting a 52.6% decline in the GPL segment.
Gross margins expanded by 510 bps to 60.2% driven by new launches and operational efficiencies.
Planned FY27 capex of ₹540 cr represents approximately 16.2% of the company's ₹3,333 cr net worth.
High-potent API portfolio expanded to 29 products with a total addressable market of $82 billion.
Company remains debt-free with cash and short-term investments totaling ₹880 cr as of June 30, 2026.
👀 What to Watch
Watch for the operationalization of the Solapur facility in early Q3 FY27 and the expected recovery of the GPL business in H2 FY27 to meet the full-year growth guidance.
Alivus Q1 FY27: 60.2% Gross Margin and Rs 540 Cr Capex Plan despite 52.6% GPL Segment Dip
Alivus Life Sciences reported Q1 FY27 revenue of Rs 640 crore, a 6.4% YoY increase, driven by a robust 26.5% growth in the non-GPL business. This growth successfully offset a sharp 52.6% decline in the Glenmark Pharma (GPL) segment caused by inventory rationalization. Profitability saw a significant boost with gross margins reaching 60.2% and EBITDA margins at 36.6%, supported by new launches and operational efficiencies. Management has guided for 10-12% revenue growth for FY27 and a substantial capex of Rs 540 crore, focusing on the Solapur facility and a new R&D center.
Confidence: HIGH
What changedThe company is successfully diversifying its revenue away from Glenmark Pharma (GPL) while achieving record-high margins through a shift toward new product launches and CDMO projects.
Why it mattersThe significant margin expansion and robust non-GPL growth demonstrate the company's standalone resilience and ability to maintain profitability despite volatility in its largest client account.
Q1 FY27 Revenue: Rs 640 crGross Margin: 60.2%FY27 Planned Capex: Rs 540 crCapex vs Net Worth: 16.2%Cash and Equivalents: Rs 880 crGPL Segment Decline: 52.6%
📅 Short termThe stock may react positively to the strong margin expansion and the management's confidence in maintaining 30%+ EBITDA margins despite raw material headwinds.
📈 Long termThe structural shift toward high-potent APIs and the large capex cycle (Rs 540 cr) suggest a transition toward higher-value products and increased capacity, supporting long-term growth.
⚠ Risk flags
- High client concentration with GPL (historically ~24% of revenue)
- Geopolitical risks impacting raw material pricing
- Execution risk on the large Solapur capex
Key Highlights
Non-GPL business grew 26.5% YoY, significantly reducing dependency on the GPL segment which fell 52.6%.
Gross margins expanded by 510 bps YoY to 60.2% due to a favorable product mix and process improvements.
EBITDA margins reached 36.6%, although management maintains a conservative full-year guidance of 30-32% due to geopolitical risks.
Planned FY27 capex of Rs 540 crore represents approximately 16.2% of the company's Rs 3,333 crore net worth.
High-potent API portfolio expanded to 29 products with a total addressable market of $82 billion, with 13 products already validated.
👀 What to Watch
Watch for the operationalization of the Solapur facility in early Q3 FY27 and monitor the expected recovery in the GPL business during H2 FY27 to validate the 10-12% annual growth guidance.
₹5.00 Final Dividend: Alivus Life Sciences Sets September 1, 2026, as Record Date
Alivus Life Sciences has fixed September 1, 2026, as the record date for a final dividend of ₹5.00 per equity share for FY 2025-26. This follows the board's recommendation made on May 14, 2026, and is subject to shareholder approval at the upcoming 15th Annual General Meeting (AGM) on September 8, 2026. The dividend represents a 250% payout on the face value of ₹2 per share. Eligible shareholders can expect payment to commence on or after September 11, 2026.
Confidence: HIGH
What changedThe company has finalized the administrative timeline (Record Date and AGM date) for the ₹5.00 final dividend previously recommended by the Board in May 2026.
Why it mattersThis confirms the cash return to shareholders, supported by the company's strong financial position, including a 25% ROCE and a low Debt-to-Equity ratio of 0.02.
Final Dividend per share: ₹5.00Face Value per share: ₹2Record Date: 01-Sep-2026AGM Date: 08-Sep-2026Dividend vs Dec 2025 EPS: 40.8%
📅 Short termThe stock price may see a minor adjustment around the ex-dividend date (near Sept 1) to reflect the ₹5.00 payout. Trading activity may remain stable as this was a previously recommended corporate action.
📈 Long termLimited; this is a routine distribution of profits. The company's long-term value remains tied to its expansion in Japan and LATAM markets and the ramp-up of its CDMO projects.
Key Highlights
Final dividend of ₹5.00 per equity share recommended for the financial year ended March 31, 2026
Record date for determining dividend eligibility fixed for Tuesday, September 1, 2026
15th Annual General Meeting (AGM) scheduled for September 8, 2026, via video conferencing
Dividend payment to be processed on or after September 11, 2026, post-shareholder approval
Dividend yield is approximately 0.37% based on the current market price of ₹1337.9
👀 What to Watch
Investors interested in the dividend must hold the shares before the ex-dividend date (typically one working day prior to the Sept 1 record date). Monitor the AGM proceedings on Sept 8 for formal approval and any management commentary on the FY27 outlook.
Rs 5.00 Dividend: Alivus Life Sciences Sets Sept 1 as Record Date for 15th AGM
Alivus Life Sciences (formerly Glenmark Life Sciences) has scheduled its 15th Annual General Meeting (AGM) for September 8, 2026. The company confirmed a final dividend of Rs 5.00 per equity share (250% of face value) for FY26, as previously recommended by the board. The record date for dividend entitlement is fixed for September 1, 2026, with payments starting from September 11, 2026. The company maintains a robust financial position with a 25% ROCE and a very low Debt/Equity ratio of 0.02.
Confidence: HIGH
What changedThe company has formalized the timeline for its 15th AGM and established the record date for the distribution of the FY26 final dividend.
Why it mattersThis confirms the cash return to shareholders and provides a scheduled platform for management to discuss the progress of their 26-product high-potent API portfolio and Japan market expansion.
Dividend per share: Rs 5.00Face Value: Rs 2Record Date: September 1, 2026AGM Date: September 8, 2026Dividend Yield (approx): 0.37%
📅 Short termThe stock may see minor price adjustments around the ex-dividend date, though the yield is relatively modest at 0.37% based on current prices.
📈 Long termLimited structural impact from this procedural filing; long-term value remains tied to the execution of capacity expansions and the 9% revenue growth target.
Key Highlights
Final dividend of Rs 5.00 per equity share of Rs 2 each recommended for FY26
Record date for dividend eligibility fixed as September 1, 2026
15th Annual General Meeting scheduled for September 8, 2026, via video conferencing
Dividend payment to commence on or after September 11, 2026, subject to shareholder approval
Company maintains a high ROCE of 25.0% and a low Debt/Equity ratio of 0.02
👀 What to Watch
Investors should ensure shares are held by the September 1 record date to qualify for the Rs 5.00 dividend. Monitor the AGM for management updates on the Solapur and Dahej capacity expansions and the ramp-up of the CDMO pipeline.
Alivus Q1 FY27 PAT Up 31.8% YoY to ₹160 Cr; Non-GPL Business Grows 26.5%
Alivus Life Sciences reported a resilient Q1 FY27 with revenue of ₹640.4 Cr, up 6.4% YoY, despite a sharp 52.6% decline in the Glenmark Pharma (GPL) segment due to inventory rationalization. The non-GPL business now dominates the mix at 88.7% of revenue, growing 26.5% YoY. EBITDA margins expanded significantly to 36.6% from 30.1% YoY, driven by a favorable product mix and new launches. The company maintains a strong balance sheet with ₹880.2 Cr in cash and is executing a major capacity expansion to reach 2,150 KL by FY27.
Confidence: HIGH
What changedThe company has successfully pivoted its revenue base away from its former parent (GPL), with non-GPL revenue now contributing nearly 89% of the total compared to 75% a year ago.
Why it mattersThe significant margin expansion to 36.6% and strong non-GPL growth demonstrate the company's ability to maintain profitability and grow independently of Glenmark Pharma's inventory cycles.
Q1 FY27 Revenue: ₹6,404 MnEBITDA Margin: 36.6%Non-GPL Revenue Contribution: 88.7%Planned Capacity Increase (by FY27E): 51%Cash and Equivalents: ₹8,802 Mn
📅 Short termThe stock may react positively to the strong margin beat and the robust growth in the non-GPL segment, which mitigates concerns over the GPL business decline.
📈 Long termThe structural shift toward complex APIs (Oncology, Iron complexes) and a nearly 90% planned capacity increase by FY29 positions the company for sustained double-digit growth.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- GPL business volatility
- Execution risk on large-scale greenfield expansion at Solapur
- Pricing pressure on mature API molecules
Key Highlights
PAT increased 31.8% YoY to ₹160.1 Cr, with PAT margins improving 480 bps to 25.0%
EBITDA margins reached 36.6%, up 650 bps YoY, despite a 7.1% sequential revenue decline
Non-GPL business grew 26.5% YoY, offsetting the 52.6% decline in the GPL segment
Total reactor capacity planned to increase 51% from 1,424 KL in FY26 to 2,150 KL by FY27E
High Potent API portfolio expanded to 29 products with an addressable market of ~$82 billion
👀 What to Watch
Watch for the management's guided recovery in the GPL business during H2 FY27 and the timely commissioning of the 350 KL Phase 1 expansion at Solapur by Q3 FY27.
32% PAT Growth and Record 36.6% EBITDA Margin in Q1 FY27 for Alivus Life Sciences
Alivus Life Sciences reported a strong Q1 FY27 with PAT rising 31.8% YoY to ₹160.1 cr and revenue growing 6.4% to ₹640.4 cr. The performance was driven by a 26.5% YoY surge in the non-GPL (non-Glenmark) business, which successfully offset a significant decline in the GPL segment. EBITDA margins reached a record high of 36.6%, well above the management's long-term guidance of 30-32%. The company remains net debt-free with a robust cash balance of ₹880.2 cr.
Confidence: HIGH
What changedAlivus achieved its highest-ever EBITDA margin of 36.6% and demonstrated a successful pivot toward non-GPL revenue streams, reducing dependency on its former parent.
Why it mattersThe margin expansion and strong free cash flow (₹90.1 cr in Q1) provide significant financial flexibility to fund the ongoing capex cycle at Solapur and Taloja without increasing debt.
Revenue (Q1 FY27): ₹640.4 crEBITDA Margin: 36.6%PAT Growth (YoY): 31.8%Cash and Equivalents: ₹880.2 crSolapur Phase 1 & 2 Capacity: 465 KLNew Capacity vs Existing: ~32.6%
📅 Short termThe stock is likely to react positively to the significant margin beat and the highest-ever PAT, despite the temporary weakness in the GPL segment.
📈 Long termThe structural shift toward high-potent APIs (29 in grid) and the 32% capacity addition at Solapur position the company for sustained double-digit growth and margin stability.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Concentration risk with GPL business expected to be flattish
- Pricing pressure on mature API molecules
- Execution risk for the Solapur expansion timeline
Key Highlights
PAT increased 31.8% YoY to ₹160.1 cr, with PAT margins expanding by 480 bps to 25.0%.
EBITDA reached a record ₹234.1 cr with a 36.6% margin, driven by a favorable product mix and operating leverage.
Non-GPL business grew 26.5% YoY, while the GPL business is expected to remain flattish for the full year FY27.
Solapur capacity expansion of 465 KL (Phase 1 & 2) is on track for completion by Q4 FY27.
Management maintains FY27 revenue growth guidance of 10-12% with EBITDA margins of 30-32%.
👀 What to Watch
Watch for the commissioning of the Solapur facility in H2 FY27 and the expected recovery of the GPL business, which is historically skewed toward the second half of the year.
Alivus Q1 PAT Surges 31.7% YoY to ₹160.1 Cr; Revenue Grows 6.4% to ₹640.4 Cr
Alivus Life Sciences (formerly Glenmark Life Sciences) reported a strong 31.7% YoY increase in net profit to ₹160.1 cr for Q1 FY27. Revenue from operations grew 6.4% YoY to ₹640.4 cr, although it saw a sequential decline of 7.1% from Q4 FY26. The company demonstrated significant cost control, with total expenses remaining nearly flat YoY at ₹450.6 cr despite the revenue growth. Profitability was further bolstered by a 149% jump in other income to ₹22.4 cr.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing a significant expansion in profit margins compared to the same period last year.
Why it mattersThe strong YoY profit growth despite modest revenue expansion indicates improved operational efficiency and a potentially better product mix, which is critical for maintaining its 25% ROCE.
Revenue (Q1 FY27): ₹640.41 crNet Profit (Q1 FY27): ₹160.08 crYoY PAT Growth: 31.7%Debt-to-Equity Ratio: 0.02Q1 Revenue vs Net Worth: 19.2%
📅 Short termThe stock is likely to react positively to the substantial YoY bottom-line growth and margin improvement.
📈 Long termLong-term value creation depends on the successful completion of ongoing capex at Solapur, Ankleshwar, and Dahej, and reducing dependency on Glenmark Pharma (GPL).
⚠ Risk flags
- Customer concentration risk (GPL previously contributed 24.4% of revenue)
- Pricing pressure on mature API portfolios
- Inventory rationalization at major customers
Key Highlights
Net profit for Q1 FY27 rose to ₹160.08 cr, a 31.7% increase from ₹121.54 cr in Q1 FY26.
Revenue from operations reached ₹640.41 cr, up 6.4% YoY from ₹601.85 cr.
Total expenses were contained at ₹450.59 cr, representing only a 0.6% increase YoY.
Basic Earnings Per Share (EPS) improved to ₹13.04 from ₹9.91 in the year-ago period.
Other income increased significantly to ₹22.40 cr from ₹8.99 cr in Q1 FY26.
👀 What to Watch
Investors should monitor the ramp-up of CDMO projects and the execution of the planned 4 new molecule launches per year in the Japan market to sustain this growth momentum.
Alivus Life Sciences FY26 EBITDA Margins Hit Record 33.6% Amid Strong Non-GPL Growth
Alivus Life Sciences reported a robust FY26 performance with revenue growing 6.9% to INR 2,552 crores and EBITDA rising 19.6% to INR 858 crores. The company achieved its highest-ever annual EBITDA margin of 33.6%, driven by a shift toward the non-GPL segment which now accounts for 71% of total revenue. Despite a INR 20 crore one-time loss due to a fire at the Dahej plant, the company remains net debt-free with a cash balance of INR 782 crores. Management has outlined an aggressive capex plan of INR 540 crores for FY27 to more than double capacity by FY28.
Key Highlights
FY26 EBITDA margins expanded by 360 basis points to 33.6%, with Q4 margins peaking at 34.4%.
Non-GPL business contribution increased to 71% in FY26 from 59% in FY22, reducing concentration risk.
Planned FY27 capex of INR 540 crores to support capacity expansion from 1,198 KL to 2,690 KL by FY28.
Added 11 new products and 49 new customers during the year, bringing the total customer base to 900.
CDMO business witnessed a meaningful recovery starting Q3 FY26 as existing projects gained traction.
👀 What to Watch
Investors should take confidence in the successful business transformation under Nirma's ownership and the significant margin expansion. The aggressive capacity expansion and reduced reliance on Glenmark provide a clear path for sustainable long-term growth.
Alivus Life Sciences FY26 Net Profit Rises 16.2% to ₹5,645 Mn; EBITDA Margins Expand to 33.6%
Alivus Life Sciences (formerly Glenmark Life Sciences) reported a steady FY26 with revenue growing 6.9% to ₹25,518 million, driven by a 13% growth in its non-GPL business. Profitability saw a significant boost as EBITDA margins expanded by 360 bps to 33.6%, resulting in a 19.6% increase in EBITDA to ₹8,577 million. The company's strategic shift under Nirma ownership is evident, with the non-GPL segment now contributing 71% of total revenue. Management has guided for high single-digit revenue growth in FY27 while maintaining margins above 30%.
Key Highlights
FY26 Revenue grew 6.9% YoY to ₹25,518 Mn, while Q4FY26 Revenue rose 6.1% to ₹6,891 Mn
EBITDA margins expanded significantly to 33.6% for FY26, up 360 bps from the previous year
Non-GPL business now accounts for 71% of total revenue, growing 13% YoY in FY26
Strong cash position with ₹7,824 Mn in cash and equivalents and free cash flow of ₹2,590 Mn in FY26
Aggressive expansion plan to more than double capacity to 2,690 KL by FY28 from 1,198 KL in FY24
👀 What to Watch
Investors should view the margin expansion and the reduced dependency on Glenmark (GPL) as strong positive indicators for long-term sustainability. The aggressive capacity expansion and CDMO turnaround provide a clear growth runway, making it a solid candidate for long-term portfolios.
Alivus Life Sciences FY26 PAT up 16.2% to ₹5,645 Mn; EBITDA Margins Expand to 33.6%
Alivus Life Sciences reported a steady 6.9% YoY revenue growth for FY26, reaching ₹25,518 Mn, driven by a 13% growth in non-GPL business. Profitability saw a significant boost with EBITDA growing 19.6% and margins expanding by 360 bps to 33.6%, exceeding previous management guidance. The CDMO segment delivered a notable turnaround with 18% YoY growth, while the company maintained a debt-free balance sheet with cash reserves of ₹7,824 Mn. Management has guided for high single-digit revenue growth in FY27 with sustained margins above 30%.
Key Highlights
FY26 Revenue grew 6.9% YoY to ₹25,518 Mn, while Q4FY26 revenue rose 6.1% to ₹6,891 Mn.
EBITDA margins expanded significantly by 360 bps YoY to 33.6% for the full year, driven by favorable product mix.
PAT for FY26 increased by 16.2% YoY to ₹5,645 Mn with a healthy PAT margin of 22.1%.
CDMO business delivered a turnaround with 18% YoY growth, offsetting a 4.9% decline in the GPL business.
Company remains debt-free with ₹7,824 Mn in cash and is expanding capacity by 465 KL at Solapur.
👀 What to Watch
Investors should find confidence in the margin expansion and the successful turnaround of the CDMO segment under Nirma's ownership. The company's debt-free status and ongoing capacity expansions at Solapur and Taloja provide a strong foundation for long-term growth.
Alivus Life Sciences Recommends ₹5 Final Dividend; FY26 Net Profit Rises 16% to ₹5,645 Million
Alivus Life Sciences (formerly Glenmark Life Sciences) reported a steady financial performance for FY26, with annual revenue growing 6.9% to ₹25,518 million. The company's net profit for the full year increased by 16.2% to ₹5,645 million, even after accounting for a one-time exceptional charge of ₹256.6 million related to new labour code regulations. For the fourth quarter, revenue reached ₹6,891 million with a profit of ₹1,627 million. Consequently, the Board has recommended a final dividend of ₹5 per share, representing a 250% payout on the face value.
Key Highlights
Recommended a final dividend of ₹5 per equity share (250% of face value of ₹2) for FY26.
Full-year Net Profit grew 16.2% YoY to ₹5,644.83 million compared to ₹4,856.27 million in FY25.
Annual Revenue from Operations increased to ₹25,518.32 million from ₹23,868.84 million in the previous year.
Q4 FY26 Net Profit stood at ₹1,626.61 million, a 14.6% increase over the ₹1,418.68 million reported in Q4 FY25.
Recognized a one-time exceptional statutory impact of ₹256.57 million due to the implementation of New Labour Codes.
👀 What to Watch
Investors should find the consistent profit growth and the ₹5 dividend attractive, signaling strong cash flow and management confidence. The company remains a robust player in the API segment with a healthy dividend yield profile.
Alivus Life Sciences FY26 PAT Up 16% to ₹5,645 Mn; Final Dividend of ₹5 Recommended
Alivus Life Sciences (formerly Glenmark Life Sciences) reported a 6.9% growth in FY26 revenue to ₹25,518.32 million. Net profit for the full year rose 16.2% to ₹5,644.83 million, even after accounting for a ₹256.57 million exceptional charge for new labor codes. For the fourth quarter, PAT grew 14.6% year-on-year to ₹1,626.61 million. The company also rewarded shareholders by recommending a final dividend of ₹5 per share, representing a 250% payout on face value.
Key Highlights
FY26 Revenue from Operations increased to ₹25,518.32 million from ₹23,868.84 million in FY25.
Net Profit for FY26 reached ₹5,644.83 million, representing a 16.2% year-on-year growth.
Board recommended a final dividend of ₹5 per equity share of ₹2 face value.
Q4 FY26 PAT stood at ₹1,626.61 million compared to ₹1,418.68 million in the previous year's quarter.
Exceptional item of ₹256.57 million recorded for statutory impacts of New Labour Codes.
👀 What to Watch
The company shows consistent growth and strong cash flow generation, supporting a high dividend payout. Long-term investors should maintain their positions given the steady performance in the core API business.
Alivus Life Sciences to Host Q4 & FY26 Earnings Call on May 15, 2026
Alivus Life Sciences Limited (formerly Glenmark Life Sciences) has scheduled its earnings conference call for Friday, May 15, 2026, at 8:30 AM IST. The call will focus on the financial performance for the fourth quarter and the full fiscal year 2025-26. This session provides a platform for management to discuss operational results and future outlook following the company's rebranding. Investors can participate via universal dial-in numbers or international toll-free lines.
Key Highlights
Earnings call scheduled for May 15, 2026, from 8:30 AM to 9:30 AM IST
Covers financial performance for Q4 FY2025-26 and the full fiscal year 2025-26
Universal dial-in numbers: +91 22 6280 1564 and +91 22 7115 8394
International toll-free access provided for USA (18667462133), UK (08081011573), and other major regions
First major annual earnings call following the name change from Glenmark Life Sciences
👀 What to Watch
Investors should attend the call to assess the company's growth trajectory and margin profile under its new identity. Key areas to watch include management's guidance on the API business and any strategic shifts post-rebranding.
Alivus Life Sciences Board Meeting on May 14 to Consider Q4 FY26 Results and Dividend
Alivus Life Sciences Limited (formerly Glenmark Life Sciences) has scheduled a board meeting for May 14, 2026, to approve its audited financial results for the quarter and full year ended March 31, 2026. In addition to the financial performance, the board will consider recommending a dividend for the fiscal year 2025-26. The trading window for designated persons is currently closed and will remain so until May 16, 2026. This announcement is a standard regulatory procedure following the conclusion of the financial year.
Key Highlights
Board meeting scheduled for May 14, 2026, to approve audited FY26 financial results
Board to consider and recommend dividend for the year ended March 31, 2026
Trading window closed from April 01, 2026, to May 16, 2026, for designated persons
First annual results announcement following the company's name change to Alivus Life Sciences
👀 What to Watch
Investors should monitor the May 14 results for operational performance and the specific dividend amount to assess yield. The stock may see volatility leading up to the announcement based on market expectations of the payout.
Alivus Life Sciences to Resume API Production at Fire-Affected Dahej Block by March 1, 2026
Alivus Life Sciences has provided a recovery update following a fire incident on February 14, 2026, at its Dahej manufacturing facility. The incident was confined to only one of the seven production blocks, primarily affecting intermediate manufacturing while API facilities remained intact. The company expects to resume API production in the affected block by March 1, 2026, and intermediate production by mid-March 2026. While some shipments will be delayed, the remaining six blocks continue to operate at full capacity, limiting the overall financial impact.
Key Highlights
Fire incident on Feb 14 was restricted to 1 out of 7 production blocks at the Dahej facility
API manufacturing facilities within the affected block were not damaged and remain unaffected
API production in the affected block is scheduled to resume on March 1, 2026
Intermediate manufacturing is expected to restart by mid-March 2026
Six other production blocks at the site remain fully operational with only minor shipment delays expected
👀 What to Watch
Investors should view this as a minor operational disruption with a clear recovery timeline. Monitor the upcoming quarterly results for any one-time costs or insurance claims related to this incident.
Alivus Life Sciences Reports Fire at Dahej API Plant; 3 Injured, Production Suspended
Alivus Life Sciences reported a fire incident at its Dahej API manufacturing facility on February 14, 2026. The fire resulted in three injuries and led to the temporary suspension of production operations at the site. While the fire was controlled within an hour, the company is currently assessing the extent of the damage and investigating the root cause. The company has confirmed that it has adequate insurance coverage to mitigate financial losses.
Key Highlights
Fire broke out at the Dahej API plant on February 14, 2026, around 23:00 Hrs
Three injuries were reported among the staff during the incident
Production operations at the facility are temporarily suspended pending damage assessment
The fire was brought under control within one hour by the factory team
The company maintains adequate insurance coverage for the potential losses
👀 What to Watch
Investors should monitor the duration of the production suspension and the subsequent assessment of financial damage. While insurance provides a safety net, any prolonged shutdown could impact short-term revenue from the API segment.
Alivus Life Sciences Q3 FY26: Record Revenue of ₹673 Cr and Highest Ever EBITDA Margin of 36.4%
Alivus Life Sciences reported its highest-ever quarterly revenue of ₹673 crores, driven by a strong recovery in the CDMO business which grew 85.3% YoY. The company achieved record EBITDA margins of 36.4%, leading to a revised upward margin guidance of 30-32% for the future. Despite a slight delay in the Solapur expansion project, the company remains net debt-free with a strong cash position of ₹733 crores. The non-GPL segment continues to be a primary growth driver, expanding 16.1% in the first nine months of FY26.
Key Highlights
Reported highest-ever quarterly revenue of ₹673 crores, up 14.4% QoQ and 4.8% YoY
EBITDA margins reached a record 36.4%, up 510 bps YoY, driven by favorable product mix and efficiency
CDMO segment showed exceptional recovery with 100% QoQ and 85.3% YoY revenue growth
Management raised long-term EBITDA margin guidance to 30%-32% from the previous 28%-30%
FY26 CAPEX guidance revised to ₹450 crores from ₹600 crores, with ₹150 crores deferred to FY27
👀 What to Watch
Investors should take note of the significant margin expansion and CDMO recovery as signs of structural business improvement. The company's debt-free status and high-potent API pipeline provide a strong long-term growth outlook.
